Winston-Salem, NC, United States of America

Jason Daniel Speake

This inventor holds 22 USPTO granted patents and 11 published patent applications, plus 2 CIPO patents and 3 EPO patents, primarily in Chemical Compounds. Top assignees: Avista Pharma Solutions, Inc., Targacept, Inc., Catalyst Biosciences, Inc.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jason Daniel Speake. Retrieved from https://idiyas.com/inventor/jason-daniel-speake

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 22 (Patent Applications = 11)

% Patents Active = 40.9

CIPO Patents = 2

EPO Patents = 3 (Patent Applications = 8)

Average Co-Inventor Count = 3.3

ph-index = 3

Forward Citations = 25(Granted Patents)

Company Filing History:

14 out of 14

Avista Pharma Solutions, Inc.

Catalyst Biosciences, Inc.

patents

4. 1 out of 2

Advitech Advisory and Technologies Sa

patents

5. 1 out of 834,513

Other

patents

Years Active: 2013-2022

Loading Chart...

Areas of Expertise:

Synthetic Process

Antiparasitic Compounds

Chemical Intermediates

Nicotinic Receptor Antagonists

JAK Inhibitors

Prostaglandin EP4 Receptor Antagonists

Single Enantiomer Compounds

Sulfonamide Derivatives

22 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11512088 - Synthetic process and intermediates (2022-11-29),

2. 11459331 - Chemical compounds (2022-10-04),

3. 11220507 - Process for the preparation of rucaparib and novel synthesis intermediates (2022-01-11),

4. 10807992 - Single enantiomer antiparasitic compounds (2020-10-20),

5. 10772331 - Antiparasitic compounds (2020-09-15),

6. 10744136 - Sulfonamide derivatives as JAK inhibitors (2020-08-18),

7. 10716770 - Nicotinic receptor non-competitive antagonists (2020-07-21),

8. 10570144 - Substituted ureas as prostaglandin EP4 receptor antagonists (2020-02-25),

9. 10556909 - Synthetic process and intermediates (2020-02-11),

10. 10342234 - Antiparasitic compounds (2019-07-09),

11. 10258582 - Nicotinic receptor non-competitive antagonists (2019-04-16),

12. 10239885 - Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist (2019-03-26),

13. 10092001 - Antiparasitic compounds (2018-10-09),

14. 9883674 - Antiparasitic compounds (2018-02-06),

15. 9686991 - Antiparasitic compounds (2017-06-27),

Title: The Innovative Contributions of Jason Daniel Speake

Introduction: Jason Daniel Speake is an accomplished inventor based in Winston-Salem, North Carolina, known for his significant contributions to the fields of chemistry and pharmaceuticals. With a remarkable portfolio of 22 patents, his innovations have the potential to address critical medical needs and enhance therapeutic approaches.

Latest Patents: Among his latest patents, Jason has developed a synthetic process involving novel intermediates related to spirocyclic azetidenyl-isobenzofuran derivatives featuring an isothiazoline moiety. These compounds are advantageous as antiparasitics. Furthermore, he has a patent that describes unique chemical compounds, including their pharmaceutically acceptable salts and compositions. Notably, these compounds act as prostaglandin EP4 receptor antagonists, proving useful for the treatment and management of pain, inflammation, and various inflammatory disorders, such as arthritis. His work outlines methods for effectively administering these compounds to treat pain, showcasing their pivotal role in modern medicine.

Career Highlights: Jason has made impactful strides in his career, having worked for esteemed organizations like Avista Pharma Solutions, Inc. and Targacept, Inc. His experience in these companies has undoubtedly influenced his inventive processes and contributions to pharmaceutical research and development.

Collaborations: Collaboration has been key to Jason’s success, as evidenced by his partnerships with noted professionals in his field, including Joe B. Perales and Daniel Yohannes. These associations have not only contributed to his growth as an inventor but have also facilitated the advancement of innovative solutions in healthcare.

Conclusion: Jason Daniel Speake's extensive patent portfolio and collaborative efforts position him as a notable inventor in the pharmaceutical sector. Through his latest patents and career achievements, he is making a lasting impact in the realm of medical innovation, paving the way for more effective treatments and therapeutic options.

Profile summary based on public USPTO records.